You are here

Adaptimmune

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

Yahoo Finance

clinical trials

head and neck cancer

urothelial cancer

Flag link:

Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy

Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy

Endpoints

TCR therapeutics

Flag link:

ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas

ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas

Fierce Biotech

soft tissue sarcomas

clinical trials

Flag link:

Second-quarter catalysts for the smaller players

Second-quarter catalysts for the smaller players

EP Vantage

Fulcrum Therapeutics

Gemini Therapeutics

Flag link:

Asco 2020 movers – cell therapy companies dominate the risers

Asco 2020 movers – cell therapy companies dominate the risers

EP Vantage

Flag link:

Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential

Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential

MedCity News

Flag link:

Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies

Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies

BioSpace

drug development

Flag link:

Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency

Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency

Endpoints

regenerative medicine

Flag link:

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Pharmaforum

Flag link:

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune reports zero responses across three T cell therapy trials

BioCentury

t-cell therapies

clinical trials

Flag link:

Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study

Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study

CP Wire

Flag link:

Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study

Flag link:

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

CP Wire

Flag link:

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

Flag link:

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug

Endpoints

TCR therapeutics

Flag link:

After setback, Adaptimmune revamps T cell study

After setback, Adaptimmune revamps T cell study

BioPharma Dive

Flag link:

Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now

Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now

Endpoints

myxoid round cell liposarcoma

cancer immunotherapy

Flag link:

These 5 Biotech Stocks Under $10 Are About to Break Out

These 5 Biotech Stocks Under $10 Are About to Break Out

TheStreet.com

Sangamo BioSciences

Flag link:

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Yahoo

Flag link:

Pages